Bluyssen H

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4582693/publications.pdf

Version: 2024-02-01

55 papers	2,491 citations	172457 29 h-index	206112 48 g-index
56 all docs	56 docs citations	56 times ranked	3856 citing authors

#	Article	IF	Citations
1	A Positive Feedback Amplifier Circuit That Regulates Interferon (IFN)-Stimulated Gene Expression and Controls Type I and Type II IFN Responses. Frontiers in Immunology, 2018, 9, 1135.	4.8	222
2	Combinatorial association and abundance of components of interferon-stimulated gene factor 3 dictate the selectivity of interferon responses.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 5645-5649.	7.1	143
3	Stat2 Is a Transcriptional Activator That Requires Sequence-specific Contacts Provided by Stat1 and p48 for Stable Interaction with DNA. Journal of Biological Chemistry, 1997, 272, 4600-4605.	3.4	135
4	ISGF3Î³ p48, a specificity switch for interferon activated transcription factors. Cytokine and Growth Factor Reviews, 1996, 7, 11-17.	7.2	129
5	The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses. Cytokine and Growth Factor Reviews, 2016, 29, 71-81.	7.2	106
6	Expression of pre-selected TMEMs with predicted ER localization as potential classifiers of ccRCC tumors. BMC Cancer, 2015, 15, 518.	2.6	105
7	Genomics and epigenomics of clear cell renal cell carcinoma: Recent developments and potential applications. Cancer Letters, 2013, 341, 111-126.	7.2	101
8	Regulation of Interferon-Î± Responsiveness by the Duration of Janus Kinase Activity. Journal of Biological Chemistry, 1997, 272, 21872-21877.	3.4	86
9	STAT2/IRF9 directs a prolonged ISGF3-like transcriptional response and antiviral activity in the absence of STAT1. Biochemical Journal, 2015, 466, 511-524.	3.7	83
10	STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNÎ³, TLR4 and IL-6 in vascular disease. Cytokine and Growth Factor Reviews, 2011, 22, 211-219.	7.2	80
11	Broadly Altered Gene Expression in Blood Leukocytes in Essential Hypertension Is Absent During Treatment. Hypertension, 2004, 43, 947-951.	2.7	73
12	Rapid determination of adenoviral vector titers by quantitative real-time PCR. Journal of Virological Methods, 2001, 93, 181-188.	2.1	65
13	STAT1-Dependent Signal Integration between IFNÎ³ and TLR4 in Vascular Cells Reflect Pro-Atherogenic Responses in Human Atherosclerosis. PLoS ONE, 2014, 9, e113318.	2.5	63
14	Damage-associated molecular pattern activated Toll-like receptor 4 signalling modulates blood pressure in l-NAME-induced hypertension. Cardiovascular Research, 2014, 101, 464-472.	3.8	61
15	Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease. Oncotarget, 2016, 7, 48788-48812.	1.8	60
16	Regulation of gene expression by dietary Ca2+ in kidneys of 25-hydroxyvitamin D3-1Î±-hydroxylase knockout mice. Kidney International, 2004, 65, 531-539.	5.2	59
17	Structure, Chromosome Localization, and Regulation of Expression of the Interferon-Regulated Mouse Ifi54/Ifi56 Gene Family. Genomics, 1994, 24, 137-148.	2.9	56
18	IFNÎ³-dependent SOCS3 expression inhibits IL-6-induced STAT3 phosphorylation and differentially affects IL-6 mediated transcriptional responses in endothelial cells. American Journal of Physiology - Cell Physiology, 2010, 299, C354-C362.	4.6	56

#	Article	IF	Citations
19	Inflammatory Response Leads to Neuronal Death in Human Post-Mortem Cerebral Cortex in Patients with COVID-19. ACS Chemical Neuroscience, 2021, 12, 2143-2150.	3.5	50
20	Thyroid cancers of follicular origin in a genomic light: in-depth overview of common and unique molecular marker candidates. Molecular Cancer, 2018, 17, 116.	19.2	48
21	Fibronectin is a hypoxia-independent target of the tumor suppressor VHL. FEBS Letters, 2004, 556, 137-142.	2.8	47
22	A type I IFNâ€“Flt3 ligand axis augments plasmacytoid dendritic cell development from common lymphoid progenitors. Journal of Experimental Medicine, 2013, 210, 2515-2522.	8.5	47
23	STAT1-mediated signal integration between IFNÎ³ and LPS leads to increased EC and SMC activation and monocyte adhesion. American Journal of Physiology - Cell Physiology, 2011, 300, C1337-C1344.	4.6	46
24	Resistance to oxidative stress by chronic infusion of angiotensin II in mouse kidney is not mediated by the AT₂receptor. American Journal of Physiology - Renal Physiology, 2005, 288, F1191-F1200.	2.7	40
25	The interferon-stimulated gene 54 K promoter contains two adjacent functional interferon-stimulated response elements of different strength, which act synergistically for maximal interferon-alpha inducibility. FEBS Journal, 1994, 220, 395-402.	0.2	35
26	Potential Approaches and Recent Advances in Biomarker Discovery in Clear-Cell Renal Cell Carcinoma. Journal of Cancer, 2015, 6, 1105-1113.	2.5	35
27	A theoretical antioxidant pharmacophore for natural hydroxycinnamic acids. Open Chemistry, 2015, 13, .	1.9	35
28	FUT11 as a potential biomarker of clear cell renal cell carcinoma progression based on meta-analysis of gene expression data. Tumor Biology, 2014, 35, 2607-2617.	1.8	34
29	Signal Integration of IFN-I and IFN-II With TLR4 Involves Sequential Recruitment of STAT1-Complexes and NFIºB to Enhance Pro-inflammatory Transcription. Frontiers in Immunology, 2019, 10, 1253.	4.8	34
30	STAT1 and IRF8 in Vascular Inflammation and Cardiovascular Disease: Diagnostic and Therapeutic Potential. International Reviews of Immunology, 2016, 35, 434-454.	3.3	33
31	Identification of STAT1 and STAT3 Specific Inhibitors Using Comparative Virtual Screening and Docking Validation. PLoS ONE, 2015, 10, e0116688.	2.5	32
32	Nitric Oxideâ€“Dependent and Nitric Oxideâ€“Independent Transcriptional Responses to High Shear Stress in Endothelial Cells. Hypertension, 2005, 45, 672-680.	2.7	29
33	Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy. Frontiers in Immunology, 2022, 13, .	4.8	29
34	In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity. European Journal of Pharmacology, 2013, 720, 38-48.	3.5	26
35	Data Mining of Atherosclerotic Plaque Transcriptomes Predicts STAT1-Dependent Inflammatory Signal Integration in Vascular Disease. International Journal of Molecular Sciences, 2014, 15, 14313-14331.	4.1	24
36	Transcriptome-based identification of pro- and antioxidative gene expression in kidney cortex of nitric oxide-depleted rats. Physiological Genomics, 2007, 28, 158-167.	2.3	21

#	Article	IF	Citations
37	Increased expression of SOCS3 in monocytes and SOCS1 in lymphocytes correlates with progressive loss of renal function and cardiovascular risk factors in chronic kidney disease. European Journal of Pharmacology, 2008, 593, 99-104.	3.5	20
38	Human and Mouse Homologs of theSchizosaccharomyces pombe rad17+Cell Cycle Checkpoint Control Gene. Genomics, 1999, 55, 219-228.	2.9	19
39	Phenotypic plasticity of Escherichia coli upon exposure to physical stress induced by ZnO nanorods. Scientific Reports, 2019, 9, 8575.	3.3	19
40	Increased SOCS expression in peripheral blood mononuclear cells of end stage renal disease patients is related to inflammation and dialysis modality. European Journal of Pharmacology, 2009, 602, 163-167.	3.5	13
41	Anti-oxidant sensitivity of donor age-related gene expression in cultured fibroblasts. European Journal of Pharmacology, 2006, 542, 154-161.	3.5	12
42	Advances in peptidic and peptidomimetic-based approaches to inhibit STAT signaling in human diseases. Current Protein and Peptide Science, 2016, 17, 135-146.	1.4	10
43	Molecular Properties and Medical Applications of Peptide Nucleic Acids. Mini-Reviews in Medicinal Chemistry, 2014, 14, 401-410.	2.4	10
44	Gene expression of energy and protein metabolism in hearts of hypertensive nitric oxide- or GSH-depleted mice. European Journal of Pharmacology, 2005, 513, 21-33.	3.5	8
45	Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA. Oncotarget, 2017, 8, 28558-28574.	1.8	8
46	Comparative screening and validation as a novel tool to identify STAT-specific inhibitors. European Journal of Pharmacology, 2014, 740, 417-420.	3.5	7
47	Genome-Wide Inhibition of Pro-atherogenic Gene Expression by Multi-STAT Targeting Compounds as a Novel Treatment Strategy of CVDs. Frontiers in Immunology, 2018, 9, 2141.	4.8	7
48	ESR Method in Monitoring of Nanoparticle Endocytosis in Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 4388.	4.1	7
49	From Transcriptome to Behavior: Intranasal Injection of Late Passage Human Olfactory Stem Cells Displays Potential in a Rat Model of Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2021, 12, 2209-2217.	3.5	7
50	CAVSâ€”Novel in silico selection strategy of specific STAT inhibitory compounds. Journal of Computational Science, 2015, 10, 186-194.	2.9	5
51	STAT2-directed pathogen responses. Oncotarget, 2015, 6, 28525-28526.	1.8	5
52	Isolation, properties and chromosomal localization of four closely linked hamster interferon-alpha-encoding genes. Gene, 1995, 158, 295-300.	2.2	4
53	Editorial: STATs and IRFs in Innate Immunity: From Transcriptional Regulators to Therapeutic Targets. Frontiers in Immunology, 2019, 10, 1829.	4.8	1
54	SINBAD, structural, experimental and clinical characterization of STAT inhibitors and their potential applications. Scientific Data, 2022, 9, 139.	5.3	1

#	Article	IF	Citations
55	Letter to the Editor. Cytokine and Growth Factor Reviews, 2016, 32, 1.	7.2	0